

# Dennis Plenker

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9046042/publications.pdf>

Version: 2024-02-01

22  
papers

1,921  
citations

567281

15  
h-index

713466

21  
g-index

24  
all docs

24  
docs citations

24  
times ranked

3841  
citing authors

#	ARTICLE	IF	CITATIONS
1	Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. <i>Cancer Discovery</i> , 2018, 8, 1112-1129.	9.4	676
2	CD74-NRG1 Fusions in Lung Adenocarcinoma. <i>Cancer Discovery</i> , 2014, 4, 415-422.	9.4	238
3	Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors. <i>Clinical Cancer Research</i> , 2016, 22, 4837-4847.	7.0	223
4	Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors. <i>Nature Communications</i> , 2018, 9, 4655.	12.8	107
5	Cell-Autonomous and Non-Cell-Autonomous Mechanisms of Transformation by Amplified FGFR1 in Lung Cancer. <i>Cancer Discovery</i> , 2014, 4, 246-257.	9.4	93
6	Intraductal Transplantation Models of Human Pancreatic Ductal Adenocarcinoma Reveal Progressive Transition of Molecular Subtypes. <i>Cancer Discovery</i> , 2020, 10, 1566-1589.	9.4	90
7	Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer. <i>Gastroenterology</i> , 2021, 160, 362-377.e13.	1.3	90
8	Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients. <i>Clinical Cancer Research</i> , 2018, 24, 1337-1343.	7.0	71
9	Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer. <i>Annals of Surgery</i> , 2020, 272, 427-435.	4.2	61
10	Organoid models for translational pancreatic cancer research. <i>Current Opinion in Genetics and Development</i> , 2019, 54, 7-11.	3.3	57
11	Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	55
12	MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I. <i>Nature Communications</i> , 2021, 12, 5505.	12.8	30
13	Patient-Derived Triple-Negative Breast Cancer Organoids Provide Robust Model Systems That Recapitulate Tumor Intrinsic Characteristics. <i>Cancer Research</i> , 2022, 82, 1174-1192.	0.9	21
14	Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer. <i>Oncotarget</i> , 2015, 6, 38458-38468.	1.8	19
15	Single-Pass vs 2-Pass Endoscopic Ultrasound-Guided Fine-Needle Biopsy Sample Collection for Creation of Pancreatic Adenocarcinoma Organoids. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 845-847.	4.4	18
16	Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-14.	3.0	17
17	Lead identification using 3D models of pancreatic cancer. <i>SLAS Discovery</i> , 2022, 27, 159-166.	2.7	17
18	Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA. <i>Clinical Cancer Research</i> , 2021, 27, 226-236.	7.0	15

#	ARTICLE	IF	CITATIONS
19	Pharmacokinetics and pharmacodynamics of new drugs for pancreatic cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 541-552.	3.3	14
20	CD74-NRG1 Fusions Are Oncogenic <i>In Vivo</i> and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 821-830.	4.1	4
21	Advances in preclinical evaluation of experimental antibody-drug conjugates. , 2021, 4, 745-754.		3
22	Loss of G2032R Resistance Mutation Upon Chemotherapy Treatment Enables Successful Crizotinib Rechallenge in a Patient With ROS1-Rearranged NSCLC. <i>JCO Precision Oncology</i> , 2018, 2, 1-6.	3.0	2